Quantcast
Home > Quotes > ALDR
x

Alder BioPharmaceuticals, Inc. Common Stock (ALDR) Quote & Summary Data

ALDR 
$13.46
*  
0.19
1.43%
Get ALDR Alerts
*Delayed - data as of Oct. 15, 2018  -  Find a broker to begin trading ALDR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 13.79 / $ 12.825
Share Volume
742,272
50 Day Avg. Daily Volume
837,052
Previous Close
$ 13.27
52 Week High / Low
$ 20.869 / $ 9.55
Market Cap
918,461,823
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
742,272
50 Day Avg. Daily Volume:
837,052

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.49

Trading Range

The current last sale of $13.46 is 40.94% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 13.79 $ 20.869
 Low: $ 12.825 $ 9.55

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform the treatment paradigm in migraine. All of our product candidates were discovered and developed by Alder scientists using our proprietary antibody technology platform coupled with a deliberate approach to design and select candidates with properties that we believe optimize the therapeutic potential for patients and commercial competitiveness. We are focusing our resources and development efforts principally on eptinezumab (ALD403), our most advanced solely-owned product candidate, in order to maximize its therapeutic and commercial potential. Eptinezumab is being evaluated in a pivotal trial program for the prevention of migraine, with a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) planned for the second half of 2018.  ... More ...  


Risk Grade

Where does ALDR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 13.26
Open Date:
Oct. 15, 2018
Close Price:
$ 13.46
Close Date:
Oct. 15, 2018

Consensus Recommendation

Analyst Info